Official leading CDC’s cruise ship program retires
The hantavirus outbreak on MV Hondius has focused the public's attention on cruise ship safety.
News Search
Search results for Statnews
Search Results
117 results found
FDA to reconsider treatment for rare cancer after its surprise rejection
The rejection of Ebvallo was part of a pattern that suggested top FDA officials had raised the bar for rare disease drugs.
Next-gen Duchenne drug from Entrada disappoints
Entrada and other companies are developing the next generation of 'exon-skipping' drugs that are designed to protect muscle function.
Public health experts are worried about the cruise ship hantavirus outbreak, but not for the reason you mig...
Isolation and contact tracing needed to contain lethal hantavirus outbreak as scientists probe human-to-human spread aboard a cruise ship.
Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
The deal will give the Italian firm Angelini a foothold in the U.S. Catalyst has three approved drugs on the market.
Oregon hospitals won’t outsource to national physician chain after all
Faced with stiff local opposition and a looming loss in court, PeaceHealth drops plan to replace Eugene Emergency Physicians with staffing chain ApolloMD.
Trump administration’s drug strategy is at odds with recent actions on funding, policy
Latest strategy document includes a nod to medication-assisted treatment and fentanyl test strips, two things the administration recently moved to limit.
Administration report on most favored nation drug pricing raises new details — and questions
White House estimate questioned by experts who see 10-year projections based on 3-year deals and little transparency on deals with 17 pharmaceutical giants.
Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
Color Health, a Silicon Valley health tech company, wants to "reinvent how cancer is managed." Here's how a virtual cancer clinic would work.
Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
The move comes after the acting Center for Drug Evaluation and Research director Tracy Beth Høeg disagreed with a staff decision.
How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
Newly mapped miniproteins could reshape biology and open targets for cancer immunotherapy, as scientists uncover thousands of overlooked genes
Why the FDA is authorizing fruit-flavored vapes
FDA approval reportedly came after Trump pressure. Public health experts are concerned about overall vape safety and politics overruling science.
Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and...
Sales of Novo Nordisk's new weight loss pill exceeded forecasts and helped close the gap with its rival, Eli Lilly
Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
Today's biotech news includes Vivek Ramaswamy winning the GOP primary for Ohio governor, CellCentric raising $220M for myeloma drug, etc.
When the path to good AI is littered with bad data
In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.
Many cancer patients don’t get genomic tests to guide treatment, study finds
Even as therapies improve, a startling number of cancer patients are not getting genomic tests that could improve their chance of survival.
Boehringer’s obesity drug shows 16.6% weight loss; more data needed
Today's biotech news covers Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and Boehringer's obesity drug
Trump’s executive order on psychedelics is the right move. But is my field ready for it?
Trump’s executive order on psychedelics is the right move, a researcher writes. But he’s not sure his field is ready.
OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations
Policy recommendations in OpenAI's blueprint for unlocking AI’s potential to change healthcare are reasonable, but also self-serving, experts say.
Ambiguous loss: a peculiar kind of grief in dementia care
Dementia leads to a grief known as ambiguous loss. American medicine and culture need to talk about it.
Dr. Glaucomflecken wants to make a stink
Will Flanary, aka Dr. Glaucomflecken, talks advocacy, cosmetic eye surgery, and ‘Scrubs’ on the “First Opinion Podcast.”
Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
At a Rome conference, biotech leaders warn FDA shifts are rattling gene therapy, as Europe pitches flexibility and the field eyes a recovery.
What you need to know about hantavirus (don’t panic)
Today's health news covers the latest on the abortion pill, rising hospitalizations related to cold temps, and fatherhood and mortality.
Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
Winnie Byanyima, executive director of UNAIDS, is pushing Merck to 'urgently' begin licensing generic production to its HIV prevention pill.